# EDGAR Filing Document

**Accession Number:** 0001088856
**File Stem:** 0001628280-25-031624
**Filing Date:** 2025-6
**Character Count:** 6384
**Document Hash:** c306cd28d7ff1a46981b9390df7c7201
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-031624.hdr.sgml**: 20250616

**ACCESSION NUMBER**: 0001628280-25-031624

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250610

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250616

**DATE AS OF CHANGE**: 20250616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CORCEPT THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0001088856
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 770487658
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-50679
- **FILM NUMBER:** 251050793

**BUSINESS ADDRESS:**
- **STREET 1:** 101 REDWOOD SHORES PARKWAY
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 650.688.8803

**MAIL ADDRESS:**
- **STREET 1:** 101 REDWOOD SHORES PARKWAY
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

?xml version='1.0' encoding='ASCII'? cort-20250610

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

June 10, 2025

Date of Report (date of earliest event reported)

**Corcept Therapeutics Incorporated** 

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-50679** | **77-0487658** |
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

**101 Redwood Shores Parkway, Redwood City, CA 94065** 

(Address of Principal Executive Offices) (Zip Code)

**(650) 327-3270**

Registrant's telephone number, including area code

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value | CORT | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

------

**Item 5.07. Submission of Matters to a Vote of Security Holders**

On June 10, 2025, Corcept Therapeutics Incorporated (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting") to consider and vote on the following proposals: 1) to elect nine directors to hold office until its 2026 annual meeting of stockholders and until their successors are duly elected and qualified, 2) to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, and 3) to approve, on an advisory basis, the compensation of the Company's named executive officers.

A total of 106,044,683 shares of the Company's common stock held by stockholders of record at the close of business on April 17, 2025 were entitled to vote at the Annual Meeting. The total number of shares voted at the Annual Meeting was 92,327,139. The voting on the three matters is set forth below:

Proposal 1 - Election of Directors. The following directors were elected to serve until the Company's 2026 annual meeting of stockholders.

---

| | | | |
|:---|:---|:---|:---|
| **<u>Director</u>** | **<u>For</u>** | **<u>Withheld</u>** | **<u>Broker Non-Votes</u>** |
| Gregg Alton | 76656278 | 738799 | 14932062 |
| G. Leonard Baker, Jr. | 74929739 | 2465338 | 14932062 |
| Joseph K. Belanoff, M.D. | 77216259 | 178818 | 14932062 |
| Gillian M. Cannon, Ph.D. | 76306553 | 1088524 | 14932062 |
| David L. Mahoney | 62676355 | 14718722 | 14932062 |
| Joshua M. Murray | 76980464 | 414613 | 14932062 |
| Kimberly Park | 70542361 | 6852716 | 14932062 |
| Daniel N. Swisher, Jr. | 76564863 | 830214 | 14932062 |
| James N. Wilson | 75426472 | 1968605 | 14932062 |

---

Proposal 2 - The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified.

---

| | |
|:---|:---|
| For | 90,463,359 |
| Against | 1,488,132 |
| Abstain | 375,648 |
| Broker Non-Votes |  |

---

Proposal 3 - The compensation of named executive officers was approved, on an advisory basis.

---

| | |
|:---|:---|
| For | 72,914,293 |
| Against | 4,195,859 |
| Abstain | 284,923 |
| Broker Non-Votes | 14,932,064 |

---

**Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits**

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **CORCEPT THERAPEUTICS INCORPORATED** | **CORCEPT THERAPEUTICS INCORPORATED** |
| Date: | June 16, 2025 | By: | /s/ Atabak Mokari |
|  |  |  | Name: Atabak Mokari |
|  |  |  | Title: Chief Financial Officer and Treasurer |

---